Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population - Wikidata - awgldk - TriplyDB

Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population

Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population

http://www.wikidata.org/entity/Q58001136

about

Selective use of sorafenib in the treatment of thyroid cancer Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib Sorafenib in metastatic thyroid cancer: a systematic review Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions Progress in molecular-based management of differentiated thyroid cancer Current status and future perspectives in differentiated thyroid cancer Autophagy in thyroid cancer: present knowledge and future perspectives 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.Alternative medical treatment for radioiodine-refractory thyroid cancers.Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer.Molecular pathogenesis and mechanisms of thyroid cancer A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.Multikinase inhibitors use in differentiated thyroid carcinoma.Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial New therapies for dedifferentiated papillary thyroid cancer Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer.Thyroid cancer: molecular aspects and new therapeutic strategies.A rare adverse reaction of sorafenib The discovery and development of sorafenib for the treatment of thyroid cancer.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review New treatment in advanced thyroid cancer.New insight into the treatment of advanced differentiated thyroid cancer.First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma: A Case Report Advanced medullary thyroid cancer: pathophysiology and management Evolving approaches to patients with advanced differentiated thyroid cancer Current understanding and management of medullary thyroid cancer.Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study.Multikinase inhibitors: a new option for the treatment of thyroid cancer.Pharmacotherapy options for advanced thyroid cancer: a systematic review.Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.

P2860

Q26752891-15A4E1A9-22E8-463E-8489-FEA04CE930A0 Q26764899-0E2EC906-A4B1-40DC-BA10-D8891501F5E9 Q26795503-E3BDD440-7F7A-42EC-8854-6848F674C341 Q26821959-8146833D-F1C2-48D6-9935-BAE4FD4E2A8E Q26828884-73FD1DF3-08E2-410C-86D2-A381CB836D87 Q26862841-186D0A05-4302-4A5A-96D9-5C0AA25DFC07 Q26863326-B8759F13-2A40-43C6-B3D8-F7E8FBD0E2D1 Q26999887-B7B3641B-0EF7-4606-9475-DFEAB12F34E9 Q27024484-25E08F48-8596-49F9-B625-C58092FF1B49 Q28086785-52AB83BF-BCD7-4EC7-A678-74D6B9F44AFC Q30367068-CB7387A0-250C-4BF4-AE90-B8D1194A3DC2 Q33569049-C90A13BB-6D7A-4A09-81B2-B6D9811E3265 Q33577870-E98C8D2C-BB00-4D44-BD17-65BDC075460F Q33682381-0494F948-3F8A-4AF0-A4DF-5DA061B12DC3 Q33704599-6974ED22-A58E-408A-85CD-94A9C9014CEA Q33927272-BA5DD1A3-4515-4D2B-BDEF-F079D3EEB109 Q34329018-62F0F87B-D305-4FBA-9188-374EDA563086 Q34538390-1BE8028D-1DBC-4C9D-8A3C-7CBCCE092CBE Q34660901-8FB3F434-F239-4D55-9A34-68DF3C2A0955 Q35057314-6570DDFE-A2D7-4B5C-A5C7-3A288F6A19CA Q35195766-CADA5DE0-DF59-40F8-91D1-10CB2E37B4E8 Q35381593-97860C2A-5EFD-458B-AF06-693EA77650AF Q35396089-2AA408E2-F8D4-4EF8-B7BB-96DBFEB0A4BB Q35603183-8EC1014E-FA3B-49B1-B608-3112B264A89D Q35988731-9463191B-A704-4BE6-9675-C2DC319953F5 Q36037051-99CF9BA6-499F-45F2-9DEE-BC7AFD71E89E Q36111541-58500A06-ADE6-4B39-A322-427119F18A7C Q36180063-363EF1CA-A5C4-4669-BB85-17521ACEFC09 Q36263304-D8C688C4-4A80-4FD8-B1D6-223878B96D14 Q36270115-9BE73FBD-CA3E-4621-A01F-B3220578BF25 Q36361115-5993D451-A93E-4F86-8EE6-7284E02CDCEC Q36528466-CEE680AA-DF3B-4F25-9801-0BF93F6D6D86 Q36565803-29B356BB-AC1E-47DC-BFC1-EAC76F79B511 Q36857218-CF079CD0-9C2E-4902-B3D9-DD2C1F599575 Q36864736-0EAB7C52-B52F-4AD5-8564-3676CC08A741 Q37247181-3286CDEE-762F-44EB-AB07-155496C158D4 Q37562646-2D6B9482-414C-4229-85C4-BF072FB7C2BF Q37921602-5F85A46E-630B-496A-BAA5-4F8217001BC4 Q37970758-F6CB5B89-47AB-4EBB-8566-2C61DEC031B1 Q37988566-75E7B6E8-2AB7-4989-98B6-8D54886A2DAB

P2860

Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population

http://www.wikidata.org/entity/Q58001136

description

article

@en

im August 2011 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2011

@uk

name

Analysis of the efficacy and t ...... study in a UK based population

@en

Analysis of the efficacy and t ...... study in a UK based population

@nl

type

label

Analysis of the efficacy and t ...... study in a UK based population

@en

Analysis of the efficacy and t ...... study in a UK based population

@nl

prefLabel

Analysis of the efficacy and t ...... study in a UK based population

@en

Analysis of the efficacy and t ...... study in a UK based population

@nl

P1433

Q58001136-07DF3352-8806-48F7-B6A7-973F4D983183

P1476

Q58001136-A4E1E155-85D0-4D01-9D06-0AB0B626E420

P2093

Q58001136-0461AA19-50CB-4171-AD8B-22C35B19E053

Q58001136-11975063-FA7E-4583-BE48-3A4581B5234B

Q58001136-1616087A-5D0E-4D0E-BC44-EBEB5CFA464D

Q58001136-8B87A6FD-359F-41DB-A896-05B5B5C8D627

Q58001136-9415D1BD-9071-4AE1-A94D-D4F157D80817

Q58001136-98740B33-976B-4291-8C11-2D682A2A0F96

Q58001136-CD3167D1-F1F2-43C7-92BF-815F68D38669

Q58001136-DDCFAB65-8368-49B7-BEA8-A685EC94C6E4

P304

Q58001136-9B4C6CC6-F02C-40CD-8C40-2F8859DFECA2

P31

Q58001136-584E6292-F89F-4581-8C91-301C2F57ED76

P356

Q58001136-8BD9AF97-B6A3-427B-B4C6-D40624C11227

P433

Q58001136-7A2DAE36-8F69-40D0-91AF-6264E7162B49

P478

Q58001136-F85EE019-EA62-470B-98D1-858864BB49BA

P50

Q58001136-FFA33373-7AEE-4274-B7BD-08F9AFEAAB9C

P577

Q58001136-11A7C527-59FE-4BB8-8BE1-D95D522C36CD

P698

Q58001136-324ACA8D-44F2-4EB4-8AFF-4F57B25D6C9E

P921

Q58001136-B7B1EEDA-12D2-495D-B637-055DCB4E019B

P356

P1433

European Journal of Endocrinology

P1476

Analysis of the efficacy and t ...... study in a UK based population

@en

P2093

Amaya Viros

http://www.w3.org/2001/XMLSchema#string

Angela Riddell

http://www.w3.org/2001/XMLSchema#string

Christopher M Nutting

http://www.w3.org/2001/XMLSchema#string

Jen Hickey

http://www.w3.org/2001/XMLSchema#string

Katie L Newbold

http://www.w3.org/2001/XMLSchema#string

Kevin J Harrington

http://www.w3.org/2001/XMLSchema#string

Merina Ahmed

http://www.w3.org/2001/XMLSchema#string

Yolanda Barbachano

http://www.w3.org/2001/XMLSchema#string

P304

315-322

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1530/EJE-11-0129

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

165

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21566072

http://www.w3.org/2001/XMLSchema#string

P921